Scholars Central

Conference abstractPublished 24 Jul 2019

Long-Term Effects of Valbenazine for Tardive Dyskinesia in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Pooled Post Hoc Analyses from KINECT 3 and KINECT 4

Authors: Erika Giraldo

Neurocrine Biosciences, Inc., San Diego, CA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Patients treated with antipsychotics, regardless of primary psychiatric diagnosis, are at risk for developing tardive dyskinesia (TD), a persistent and often irreversible movement disorder which is also potentially disruptive and disabling. Valbenazine (INGREZZA®) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat TD in adults. The current objective was to evaluate the long-term effects of valbenazine on TD in adults with schizophrenia/schizoaffective disorder (SZD) or mood disorder (MD). Methods: Pooled data were analyzed post hoc from two Phase 3 studies, KINECT 3 (NCT02274558) and KINECT 4 (NCT02405091) in adults with TD and SZD or MD. KINECT 3 had a 6-week double-blind placebo-controlled period, 42-week double-blind extension, and 4-week drug-free washout. KINECT 3 participants who were initially randomized to valbenazine continued into the extension period at the same dose (40mg or 80mg) and were included in this analysis.1,2 KINECT 4 participants initiated valbenazine dosing at 40mg and were escalated to 80mg if 40mg was tolerated and a clinician global rating was “minimally improved” or worse for a total of 48-weeks of open-label treatment with a 4-week drug-free washout. Participants could return to 40mg based on tolerability.3 TD was assessed using the Abnormal Involuntary Movement Scale (AIMS) total score (sum, items 1-7; scored by blinded central raters in KINECT 3 and site raters in KINECT 4) and Clinical Global Impression of Change -Tardive Dyskinesia (CGI-TD) scores (range from 1 “very much improved” to 7 “very much worse”). Psychiatric scales included Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) for SZD participants; or Montgomery-Åsberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) for MD participants; and Columbia-Suicide Severity Rating Scale (C‑SSRS) for all participants. Results: Analyses included 209 participants with SZD (40mg=75; 80mg=134) and 95 with MD (40mg=32; 80mg=63). At Week 48, significant mean (SEM) improvements from baseline were observed for AIMS total score: SZD (40mg, ‑5.0 [0.92]; 80mg, -8.5 [0.58]; both, P<0.0001); MD (40mg, ‑7.3 [1.58], P=.0004; 80mg: -8.5 [0.89], P<.0001). AIMS total score change from baseline to Week 52 (end of washout) showed some loss of effect. Similarly, at Week 48 CGI-TD mean (SEM) scores were: SZD (40mg, 2.2 [0.15]; 80mg, 1.9 [0.10]); MD (40mg, 2.3 [0.25]; 80mg: 1.7 [0.13]), indicative of “minimally improved” or better. Psychiatric status

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Erika Giraldo”